1,25-dihydroxyvitamin D3 enhances the ability of transferred CD4+ CD25+ cells to modulate T helper type 2-driven asthmatic responses

The severity of allergic diseases may be modified by vitamin D. However, the immune pathways modulated by the active form of vitamin D, 1,25‐dihydroxyvitamin D₃ 1,25(OH)₂D₃], are yet to be fully elucidated. In this study, naturally occurring CD4⁺ CD25⁺ cells from the skin‐draining lymph nodes (SDLN) of mice treated with topical 1,25(OH)₂D₃ had an increased ability to suppress T helper type 2 (Th2) ‐skewed immune responses. CD4⁺ CD25⁺ cells transferred from mice treated with topical 1,25(OH)₂D₃ into ovalbumin (OVA) ‐sensitized mice challenged intranasally with OVA 18 hr later, significantly suppressed the capacity of airway‐draining lymph node (ADLN) cells to proliferate and secrete cytokines in response to further OVA stimulation ex vivo. The CD4⁺ CD25⁺ cells from 1,25(OH)₂D₃‐treated mice also reduced airway hyperresponsiveness and the proportions of neutrophils and eosinophils in bronchoalveolar lavage fluid (BALF). To test the effect of 1,25(OH)₂D₃ on cells able to respond to a specific antigen, CD4⁺ CD25⁺ cells were purified from the SDLN of OVA‐T‐cell receptor (TCR) transgenic mice treated 4 days earlier with topical 1,25(OH)₂D₃. CD4⁺ CD25⁺ cells from OVA‐TCR mice treated with 1,25(OH)₂D₃ were able to alter BALF cell content and suppress ADLN responses to a similar degree to those cells from non‐transgenic mice, suggesting that the effect of 1,25(OH)₂D₃ was not related to TCR signalling. In summary, topical 1,25(OH)₂D₃ increased the regulatory capacity of CD4⁺ CD25⁺ cells from the SDLN to suppress Th2‐mediated allergic airway disease. This work highlights how local 1,25(OH)₂D₃ production by lung epithelial cells may modulate the suppressive activity of local regulatory T cells.